Background: Yes-associated protein (YAP) overexpression is reported to be associ-
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common hepatic primary malignancy and the third leading cause of cancer-related mortality worldwide. 1 Although multiple therapeutic modalities are available to treat HCC, mortality is still unacceptably high. Recently, research on tumour signal transduction pathways have revealed important pathway proteins that could be exploited for treatment targets, and these approaches have increased patient survival. 2, 3 The hippo signalling pathway regulates cell proliferation and apoptosis during normal development and the Yesassociated protein (YAP) is a major effector of this pathway-YAP overexpression causes hepatocellular tumour cell transformation. 4 YAP is more greatly expressed in HCC compared to non-tumour specimens, and overexpression of YAP is associated with clinicopathological features of HCC, [5] [6] [7] however, data have been inconsistent and heterogeneous. Therefore, this meta-analysis was performed to evaluate the relationship between YAP overexpression and HCC.
| METHODS

| Literature search strategy
A search was conducted with PubMed, EMBase, Wangfang and the Chinese National Knowledge Infrastructure (CNKI) for studies published from 1 January 1996 until 1 September 2016. Relevant studies were identified using the following terms: ("hepatocellular carcinoma"
or "liver cancer" or "HCC") and ("YAP"). Article languages were limited to English and Chinese. All searched studies were retrieved and references were reviewed to locate additional eligible studies.
Authors were emailed for studies without sufficient data. We manually searched to ensure that all available studies were included in this meta-analysis.
| Inclusion and exclusion criteria
Studies included measured YAP expression in HCC using immunohistochemistry. HCC was diagnosed histopathologically. Controls were confirmed to be HCC-free. Samples used were tumours and adjacent non-tumour tissues. Only full-text articles were included. Cases were excluded if they mentioned other cancer types, were case reports, letters, or reviews lacking original data or non-full-text papers. No article was duplicated in the analysis.
| Assessment of study quality
Study quality was assessed using a Newscastle-Ottawa Quality Assessment Scale. 8 Two researchers appraised the methodological quality independently. As shown in Table 1 , selection method, comparability and exposure assessment method of cases and controls were included in the assessment system. Study "stars" (1-10) referred to their fitness for being incorporated into the meta-analysis. Studies with <5 stars were considered to be "low-quality" studies and were excluded.
| Data extraction
Full-texts of candidate articles were reviewed by two independent investigators and data were extracted and sorted. If results were in disagreement, a third investigator resolved the inconsistency. Data extracted from selected articles included the first author's name, publication year, country, numbers of cases and controls, YAP expression in HCC and adjacent normal tissue, and clinicopathological features.
| Statistical analysis
The meta-analysis was performed using STATA 12. Otherwise, a random-effects model (DerSimonian and Laird model) was used. Sensitivity analyses were used to assess stability of metaanalysis results and sensitivity analysis was performed by removing a specific study from the meta-analysis. Begg's funnel plots were used to evaluate publication bias and two reviewers analysed data independently and obtained the same conclusions.
| RESULTS
| Study characteristics
A total of 454 records, 210 from PubMed, 110 from EMbase, 108
from the CNKI and 26 from the Wanfang Database were found using our search strategy. The complete literature selection process appears in Figure 1 . Study characteristics of those chosen appear in Tables 2-4 .
| Heterogeneity and sensitivity analysis
Analysis of the correlation of YAP expression between HCC and adjacent non-tumour tissue revealed that two studies 5, 9 had substantial influence over the data and overall estimates remained stable. Based 
Key points
• The literature that describes Yes-associated protein (YAP) overexpression and clinicopathological aspects of hepatocellular carcinoma (HCC) offer different results.
• Yes-associated protein overexpression contributes to hepatobiliary carcinoma.
• We confirm consistencies between YAP overexpression and HCC clinicopathological features.
• Yes-associated protein overexpression is associated with vascular invasion, cellular differentiation, tumor size and TNM tumor stage.
| Publication bias
Funnel plots were symmetrical, and Egger's and Begg's tests suggested no obvious publication bias in the analysis of correlations between YAP overexpression in HCC and clinicopathological features ( Figure 2B , Table 5 ).
| Meta-analysis results
Within four records We used the Newscastle-Ottawa Scale to assess study quality, selection method, comparability and exposure; the assessment method was also comprehensively evaluated. Article "stars" were at least 7,
| DISCUSSION
indicating that all included studies were of high quality. The Egger's and Begg's tests indicated no significant publication bias.
Overall, eight studies were included and six contained data regarding YAP expression and HCC and adjacent non-tumor tissues, suggesting that YAP expression between HCC and adjacent tissues differed. Funnel plots were symmetrical. There was evidence of significant heterogeneity before excluding work by Han and Xu.
5,9
Sensitivity analysis indicated that two studies 5, 9 affected metaanalysis stability, and after eliminating these two studies, heterogeneity significantly improved.
Work by Han and Xu 5,9 described YAP expression in HCC and non-tumorous tissue and reported P-values <.01, which supports our meta-analysis that YAP expression in HCC was significantly higher than in adjacent tissues, and YAP overexpression contributed to the occurrence of HCC.
We also noted that YAP overexpression is related to poor differentiation, more venous infiltration, TNM stage III-IV, and tumours larger 6, 9, 24 suggested that YAP expression was related to tumour size. Thus, YAP overexpression may be a risk factor for the formation of HCC.
As shown in Table 4 
